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Abstract
Background: Pain is often cited as one of the worst features of medical abortion. Further, inadequate pain
management may motivate some women to seek unnecessary clinical care. There is a need to identify effective
methods for pain control in this setting.
Methods/Design: We propose a randomized, placebo-controlled trial. 576 participants (288 nulliparous; 288 parous)
from study sites in Nepal, South Africa and Vietnam will be randomly allocated to one of three treatments: (1) ibuprofen
400 mg PO and metoclopramide 10 mg PO; (2) tramadol 50 mg PO and a placebo; or (3) two placebo pills, to be taken
immediately before misoprostol and repeated once four hours later. All women will be provided with supplementary
analgesia for use as needed during the medical abortion. We hypothesize that women receiving prophylactic analgesia
will report lower maximal pain scores in the first 8 h following misoprostol administration compared to women receiving
placebos for medical abortion through 63 days’ gestation. Our primary objective is to determine whether prophylactic
administration of ibuprofen and metoclopramide or tramadol provides superior pain relief compared to analgesia
administration after pain begins, measured during the first eight hours after misoprostol administration. Secondary
objectives include identifying covariates associated with higher reported pain scores; determining any impact of the
study medicines on medical abortion success; and, qualitatively exploring women’s physical experiences of medical
abortion, especially related to pain, and how can they be improved. Data sources include medical records, participant
symptom diaries and interview data obtained on the day of enrollment, during the medical abortion, and at follow-up.
Participants will be contacted via telephone on day 3 and return for follow-up will occur approximately 14 days after
mifepristone, concluding study participation. A subset of 42 women will also be invited to undergo in-depth qualitative
interviews following study completion.
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Discussion: Although pain is one of the most common side effects encountered with medical abortion, little is known
about optimal pain management for this process. This multi-arm trial design offers an efficient approach to evaluating
two prophylactic pain management regimens compared to use of pain medication as needed.
Trial registration: ACTRN12613000017729 (Prospectively registered 8/1/2013).
Keywords: Medical abortion, Mifepristone, Misoprostol, Pain management
Plain English summary
Pain is a predictable feature of the medical abortion
process, and for some women, pain may be intense.
Although pain is the most common side effect encoun-
tered with medical abortion, little is known about opti-
mal pain management during this process, and there is a
clear need to identify effective methods for pain control.
Our study is a randomized, placebo-controlled trial of
different options for pain relief during early medical
abortion with mifepristone and misoprostol. It is
designed to determine whether initiating different medi-
cines before pain begins (tramadol, a weak narcotic, or
ibuprofen plus metoclopramide, an anti-nausea medi-
cine) is superior to taking medicines only once pain
begins during the medical abortion process.
Background
Pain is a predictable feature of the medical abortion
process, and for some women, pain may be intense
[1, 2]. Pain is typically most acute following adminis-
tration of prostaglandins or their analogues and most
intense prior to pregnancy expulsion, typically occurring
approximately 4 h following misoprostol administration
for the combined regimen (mifepristone and misoprostol)
for medical abortion [3–5]. As pain is often cited as one of
the worst features of medical abortion [6], and given that
inadequate pain management may motivate some women
to seek unnecessary clinical care, there is a clear need to
identify the most effective methods of pain control during
the abortion process.
Current guidelines from the World Health Organization
(WHO) recommend use of non-steroidal anti-inflammatory
drugs (NSAIDs) during medical abortion for pain manage-
ment; however, these recommendations draw from limited
available evidence [7–11]. WHO notes that further research
to determine best pain management options, including tim-
ing of medication administration, for medical abortion pro-
vided both before and after twelve weeks is a priority [12].
The NSAID Ibuprofen is commonly recommended for
pain management with medical abortion. Raymond et al.
demonstrated that prophylactic ibuprofen alone does not
sufficiently address women’s pain with early medical abor-
tion (EMA, generally defined as abortion up to 63 days
from last menstrual period) [13]. However, we propose to
investigate the effects of prophylactic administration of
ibuprofen co-administered with metoclopramide because
we hypothesize that the combination of these medicines
may offer improved pain control as well as a practical ap-
proach to outpatient pain management that builds on
current recommendations for the provision of NSAIDs to
treat pain with EMA [12].
Nausea is reported by approximately half and vomiting
is reported by one-third of all women undergoing med-
ical abortion [14]. These symptoms are related both to
the physiologic effects of early pregnancy as well as
known side effects of the abortifacients, particularly
misoprostol. Metoclopramide is an anti-emetic and pro-
kinetic agent that is used commonly to treat a variety of
gastrointestinal disorders, including nausea and vomiting
associated with pregnancy [15]. It is rapidly and well-
absorbed following oral administration with peak plasma
concentrations achieved at 1–2 h after ingestion. Typically,
it is prescribed for use every four to eight hours.
No studies have previously investigated the use of oral
metoclopramide as part of a pain control regimen for
EMA. However, several small randomized trials describe
the use of adjuvant metoclopramide with intravenous
patient-controlled analgesia (IV PCA) during second tri-
mester medical abortion [16–18]. Women receiving IV
metoclopramide 10 mg generally reported less nausea
and vomiting and lower pain scores compared to con-
trols. Though not statistically significant, it was also
observed that women receiving metoclopramide tended
toward shorter induction-to-delivery intervals (ranging
from 3–7 h). It has been theorized that metoclopramide
may help coordinate smooth muscle contraction of the
uterus and fallopian tubes following exposure to prosta-
glandins, resulting in decreased discomfort and improved
expulsive force [17]. We postulate that metoclopramide
not only offers potential to improve the acceptability of
medical abortion among some women by reducing side
effects, but it may also expedite pregnancy expulsion and
contribute to an overall decrease in pain when provided as
adjuvant therapy to ibuprofen.
In addition, we propose to investigate whether prophy-
lactic administration of tramadol may be superior to
placebo in reducing women’s pain with EMA. Tramadol
is a non-traditional opioid that is structurally similar to
codeine and morphine; it is indicated for the use of
acute and chronic moderate-to-severe pain. Unlike
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morphine and codeine, tramadol is a racemic mixture of
both enantiomers, and they and their metabolites con-
tribute to analgesia via different mechanisms. They bind
centrally to μ-opioid receptors as well as inhibit norepin-
ephrine and serotonin reuptake, resulting in inhibition
of both transmission and perception of pain [19].
Following oral administration, tramadol is rapidly and
almost completely absorbed with peak plasma concen-
trations achieved at 1.6–1.9 h. It also can be provided
every four hours for pain.
The most common side effects associated with trama-
dol include nausea, dizziness, drowsiness and vomiting;
these are reported at a low frequency among users, ran-
ging between 2–8%, equivalent to the frequency of these
side effects among users of other opioid medications
[20]. However, tramadol is associated with a lower
incidence of respiratory depression, constipation and
abuse compared to morphine and codeine. Tramadol’s
performance as a pain medication, safety profile and
tolerability contribute to its recognition as an important
pain medication for short-term and chronic pain man-
agement across a variety of indications. A number of
international guidelines specifically recommend trama-
dol, not just weak opioids, as a choice medication for
pain management [20–23].
Tramadol, provided intravenously and intramuscularly,
has been described as an effective agent to treat labor
pain as well as pain associated with medical abortion in
the second trimester [18, 24, 25]. In addition, women
randomized to receive a tramadol rectal suppository
prior to surgical abortion required less intraoperative
anesthesia and rescue analgesia than women who
received indomethacin (an NSAID); they also reported
lower postoperative pain scores [26]. A small number of
multiparous women undergoing IUD insertion were
randomized to oral tramadol, naproxen (an NSAID) or
placebo one hour prior to their procedure; women who
received tramadol reported the lowest pain scores [27].
This limited evidence demonstrates that tramadol may
be an effective agent to treat pain associated with uterine
cramping, perhaps superior to NSAIDs, and suggests a
role to address pain from EMA.
Evaluation of new pain management strategies to pre-
vent or minimize pain accompanying medical abortion is
important for improving the quality of medical abortion
services for women. A major challenge in evaluating
new treatments for clinical care is the considerable time
and resources needed for conducting randomized, con-
trolled trials. Given the evidence regarding prophylactic
ibuprofen administration alone and paucity of data
informing pain management with EMA overall, a multi-
arm trial design offers an efficient approach to evaluat-
ing two experimental treatments compared to a placebo
control arm rather than conducting multiple RCTs [28].
The primary objective of this study is to determine
whether prophylactic administration of ibuprofen and
metoclopramide or tramadol and placebo are superior to
placebo alone combined with analgesia administration
after pain begins during the medical abortion process,
measured in the first eight hours following misoprostol
administration. Secondary objectives include identifying
covariates other than the pain management regimen that
may be associated with higher reported pain levels. Also,
we will report if prophylactic use of these medications
impacts the effectiveness of the medical abortion regimen.
Finally, among a subset of participants, we will qualita-
tively explore women’s physical experiences of medical
abortion, especially related to pain, and share insights into
how they might be improved from women’s perspectives.
Methods
Study design
We propose a multi-center, three-arm, blinded, random-
ized, controlled trial; participants will be randomized in
a 1:1:1 allocation ratio to either one of two active
prophylactic pain management arms or a placebo arm
while undergoing early medical abortion (≤63 days from
last menstrual period) with mifepristone and misopros-
tol. All participants will also have access to additional
analgesia to use as needed at their own discretion during
the medical abortion process (See Fig. 1).
When a woman presents requesting EMA, she will be
screened for inclusion and exclusion criteria; only
eligible women who provide their informed and volun-
tary consent will be recruited to the trial. Consent for
the abortion procedure will be obtained separate from
the consent to participate in research.
Participants will ingest mifepristone 200 mg orally at the
study site on day one. Approximately 24–48 h after taking
mifepristone, women will take the first dose of study med-
icines at home immediately prior to use of 800 mcg miso-
prostol, by vaginal (Nepal, Vietnam) or sublingual (South
Africa, Vietnam), routes according to the standard prac-
tice at the site. The second dose of study medicines will be
taken four hours later. Women will complete a diary to
note the times the medications were taken and pain levels
recorded on a 0-10 scale. Women will be contacted via
telephone between days three to five after taking mifepris-
tone. This telephone contact, lasting approximately ten
minutes, will review the maximum level of pain partici-
pants experienced during the first 8 and 24 h after miso-
prostol, their adherence to the study medicine regimen
and use of additional analgesia. Women will also be asked
to attend clinic for a scheduled follow-up appointment
approximately two weeks after initiating the medical abor-
tion process. At this visit, an assessment for completion of
the medical abortion will be performed, the diary will be
reviewed, and additional data will be collected regarding
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acceptability of the medical abortion overall, the pain
medication regimens, and the pain experience.
Setting and participants
Women will be recruited from sites where safe and legal
medical abortion services are well-established in diverse
and regionally representative low resource countries.
Specifically, the Paropkar Maternity and Women’s
Hospital in Kathmandu, Nepal, Job Tabane Hospital in
Rustenburg, South Africa, and the National Hospital of
Obstetrics and Gynecology in Hanoi, Vietnam, are host-
ing this study.
All participants will be administered mifepristone in
clinic to initiate the medical abortion and will be instructed
Fig. 1 CONSORT/Spirit Flow Diagram
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to use misoprostol and the study medicines at home
according to standard practice. In Nepal and Vietnam,
women also have the option to use misoprostol (and for
the purposes of this trial, the study medicines) under super-
vision in the clinic until the time of expulsion; typically, a
minority of women undergoing medical abortion at these
sites choose to complete the medical abortion in clinic.
Women ages 18 years and older seeking medical abor-
tion up to 63 days’ gestation at these sites, who report a
willingness to participate in the study, are fluent in the
language of site, possess sufficient literacy to adhere to
study instructions and complete home self-assessments,
and agree to be contacted by telephone are eligible for
participation. Women will be excluded if any pregnancy
abnormalities (e.g. multiple gestation, molar, ectopic, or
non-viable pregnancy) or allergies/contraindications to
use of mifepristone and misoprostol or any of the study
medications are detected. Additionally, women who
report no access to a time-keeping device or an inability
to return to the study site with no option for telephone
contact will be excluded.
Intervention
Participants will be randomized to receive one of the
following:
(1)ibuprofen 400 mg PO and metoclopramide 10 mg PO;
(2)tramadol 50 mg PO and a placebo; or
(3)two placebo pills, to be taken immediately before
misoprostol and repeated once four hours later.
All women will also be provided with additional
analgesia (4 tablets of ibuprofen 400 mg and 2 tablets of
codeine 10 mg/ paracetamol 500 mg) for use as needed
during the medical abortion at their discretion. All
women will receive detailed instructions about all study
medicines, including the timing, route and indications
for use of the various medications they are supplied.
The trial statistician at WHO centrally generated the
randomization and treatment allocation scheme, based
on computer-generated random permuted blocks (using
STATA statistical software, version 10.0, College Station,
TX) to share with the supervising trial pharmacist. Block
sizes will be randomized and information on block sizes
will be masked to all investigators during treatment allo-
cation across study arms. Treatment allocation is strati-
fied according to parity (sample will be 50% nulliparous
and 50% parous in each treatment arm) in order to avoid
imbalances across the three treatment groups. All study
medicines are pre-packaged in opaque bags, labelled
with subject numbers and sealed off-site in accord with
the centrally-generated randomization and treatment
allocation scheme, supervised by a skilled pharmacist,
then transported for dispensing at research sites.
Women will receive blind treatments from study staff at
research sites by sequential assignment of the pre-
packaged study medicines according to subject number.
Study outcomes
Our primary outcome is maximum self-reported pain
during the first 8 h after misoprostol administration and
use of the first dose of study medicines. Pain will be
measured by an 11-point numeric visual analogue scale
(VAS); values range from 0–10 where 0 is equivalent to
no pain and 10 is worst possible pain.
Secondary outcomes include:
o Maximum pain as measured by VAS over first 24-h
period
o Use of any additional analgesic medication
o Use of any supplemental narcotic
o Effectiveness of the medical abortion regimen, defined
as successful completion without additional surgical
intervention.
Sample size
The sample size is based on our primary outcome. VAS
measurements for self-assessment of pain have been
extensively validated in the literature [29]. Previous
research found that the maximum VAS score with early
medical abortion with mifepristone and misoprostol was
7, ranging from 5–8 [7–10]. Studies have also reported
that the minimally clinically significant difference in
VAS scores is between 1.5 and 2 [30, 31]. In order to
detect a reduction in maximum VAS scores in the first 8
h from 7 to 5.5, assuming a standard deviation of 3.0,
using a two-sided alpha of 0.05 and power of 90% while
accounting for 10% loss to follow up, we will need 96
women in each study arm. We also want to determine
the effect of prophylactic medication by parity among
nulliparous and parous women. Due to stratification by
parity, we plan to enroll a total of 576 women, 192
women per treatment arm, half of whom will be nul-
liparous. Because our treatment arms are independent of
one another, and the aim being to assess independently
the efficacy of ibuprofen and metoclopramide regimen
or tramadol in reducing pain, we do not have to account
for a multiplicity adjustment in our sample size calcula-
tions. A multiplicity adjustment for sample size is needed
in multiple comparisons of interventions containing
related regimens or in case of interventions with a dose-
response relationship [28].
Data collection
Data will be collected from participants at four time points:
1.) At enrollment, women will be asked to provide basic
demographic information and medical history, and
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clinical information following assessment by a health
provider will be recorded.
2.) Following initiation of the medical abortion process
with mifepristone, women will be asked to record
details about the timing and use of misoprostol and
study medicines as well as any additional analgesia,
self- assessments of pain and the experience of known
side effects associated with medical abortion and the
study medicines, such as nausea, vomiting or bleeding.
As the majority of participants will be taking
misoprostol and the study medicines at home, we are
relying on women to record their own data. They will
be provided a detailed orientation to the diary and the
imperative for timely and complete data collection will
be communicated prior to discharge from the clinic.
3.)Women will be contacted via telephone on days
three to five following mifepristone use (days 1–3
after misoprostol) to document women’s pain
assessments during the first 8 and 24 h after
misoprostol, use of study medicines and any
additional analgesia.
4.) Approximately two weeks following enrollment,
women will be asked to attend clinic to determine
abortion completion and to collect clinical data,
verify and record data from their personal diaries
and to inquire about the acceptability of the medical
abortion process, study medicines, additional
analgesia and study procedures overall.
Any discrepancies in data collected at the time of
telephone contact, recorded in the participant diary or
reported at follow up will be resolved at the time of
follow up with the woman. Data collection forms and
participant diaries will be prepared in English; these
forms will be translated as necessary and translations
verified prior to use in the respective countries. All
required measures to protect participant confidentiality
during data collection and data management will be
implemented according to GCP standards.
Data management
Guidelines were prepared for interviewing and collecting
data, recording data on paper case report forms and
entering these data in OpenClinica, a GCP-compliant,
password-protected, web-based application for data
entry and management. All data collectors, data entry
operators and data managers at the sites will be trained
before initiating the trial. Participating centers are re-
quested to first record data on paper data collection
forms and then double-enter data into the online OC
system as soon as possible (minimally on a weekly basis).
Queries for missing data, data errors and inconsistencies
are automatically generated in the OC system and
resolved accordingly by the local data manager with the
assistance of the clinical trial manager at WHO. All par-
ticipating sites will be subject to periodic on-site study
monitoring visits for trial audits as part of our plan to
assure quality; these visits will be lead by the trial sponsor
and have oversight by the WHO clinical trial manager.
Data analysis
Standard datasets will be generated from the final
OpenClinica study database for analysis. A study partici-
pant flowchart will be prepared, as per CONSORT
guidelines to present the numbers of women screened,
randomized, allocated interventions, discontinued or lost
to follow-up and analyzed [32]. The rate of follow-up of
participants across study arms will be compared using
the Kaplan-Meier survival method. Baseline characteris-
tics, and results for primary and secondary outcomes for
all randomized participants will be summarized accord-
ing to treatment allocation. For categorical variables, the
frequencies and crude percentages will be reported.
Type and frequency of additional analgesia use and med-
ical abortion effectiveness will be treated as categorical
variables. For quantitative variables, crude mean esti-
mates and standard errors will be provided for normally
distributed variables; and medians, interquartile ranges,
minima and maxima will be reported for variables with
skewed distributions. Pain scores will be treated as con-
tinuous variables with comparison between study arms
being done using parametric tests as long as normality
assumptions hold. In this case, Analysis of Variance
(ANOVA) will be applied to test for differences in pain
score between the allocated arms, using both ITT and
per-protocol (PP) study populations, A generalized linear
model (GLM) using a normal distribution and an iden-
tity link will be used to compare pain levels between
arms while adjusting for parity and country,
randomization stratification factors. In the case of a
skewed distribution of VAS pain scores, a Kruskal-
Wallis non-parametric test will be used to crudely com-
pare median pain scores between the three arms; in this
case, transformation of the pain scores to a normal dis-
tribution may be considered prior to using the GLM
model.
The GLM model will also be used to evaluate import-
ant covariates other than pain medication regimen
associated with higher reported pain levels as long as
normality assumptions hold. Two-sided tests and 5% sig-
nificance levels will be used with 95% confidence inter-
vals for all relevant parameters. The SAS statistical
package will be used for the statistical analyses [33].
Open-ended questions will be listed and coded for
meaningful comparisons of their distributions.
Log-binomial regression will be used to estimate and
compare the risk of exposure to the study interventions
on secondary outcomes, including use of any additional
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analgesic medication, use of any supplemental narcotic
and effectiveness of the medical abortion regimen, while
adjusting for randomization stratification factors.
In-depth interviews
A subset of women (n = 42) will be invited to participate
in an in-depth interview after completion of their med-
ical abortion. Because young age and parity have been
associated with pain during medical abortion, we plan to
purposely recruit half the sample of 42 women for
in-depth interviews to be nulliparous (and most will also
be young). To try to capture a range of pain experiences,
we will also purposively sample women who report dif-
ferent pain intensities associated with their medical
abortion identified at the time of the follow-up interview.
These interviews will be audio-recorded, transcribed
verbatim, and coded using the qualitative software Atlas
Ti. Two investigators will independently conduct a con-
tent analysis of the interview transcripts using the same
software to identify emerging themes.
Safety considerations
We recruited clinical pharmacists to conduct a system-
atic evaluation of the literature regarding any potential
drug interactions among those proposed for use in the
trial. Theoretically, the use of misoprostol, which is a
prostaglandin analogue, with NSAIDs could result in a
drug interaction which decreases the effectiveness of the
medical abortion. Despite this theoretical concern,
clinical studies have not demonstrated a difference [13,
34, 35]. Further, no known drug interactions between
tramadol and mifepristone or misoprostol, metoclopra-
mide and mifepristone or misoprostol or between
ibuprofen and metoclopramide have been reported [36].
Metoclopramide has been linked to an increased risk
of acute dystonic reactions, affecting 0.2% of users [37].
Tardive dyskinesia can manifest as involuntary and
repetitive movements of the body, even after the drugs
are no longer taken and can be irreversible (Package
labeling for metoclopramide, TEVA pharmaceuticals USA).
In our investigation, participants will have short-term (two
doses) and low-dose exposure to this medication, mitigating
the risk of this rare occurrence.
Adverse events
Adverse events are defined as any untoward medical oc-
currence that a participant may experience during the
course of the study, regardless of its relationship to study
product use. We will record only new events, or a wors-
ening of an existing condition, as AEs in the trial. In our
study, the following routine trial measurements will not
be considered AEs because they are defined as trial end-
points: abortion; and symptoms associated with medical
abortion (e.g. pain, vaginal bleeding, fever, chills, nausea,
vomiting and diarrhea).
A serious adverse event (SAE) is defined as any unto-
ward medical occurrence that:
 Is life threatening or results in death.
 Requires in-patient hospitalization or prolongs exist-
ing hospitalization.
 Results in persistent or significant disability/incapacity.
 Is a congenital abnormality/birth defect (in the offspring
of a participant).
 Jeopardizes participant and required medical/
surgical intervention to prevent serious outcome, or
 Any other event that the investigator considers serious.
Details about each AE will be recorded on an Adverse
Event Form, and about SAEs on a Serious Adverse Event
Form. In accordance with ICH guidelines, these forms
will require the following information to be collected:
diagnosis, onset date, resolution date, source of informa-
tion, severity, treatment given, relationship to study
product, action taken, and comments. The forms will be
completed by study staff and the Principal Investigator
informed as soon as possible. All SAEs must be reported
to the WHO project manager within 24 h of when the
PI was notified; WHO will facilitate timely reporting to
the required regulatory and advisory bodies providing
oversight to the study. Clinical trial insurance has been
secured to cover participants in the study at all collabor-
ating sites.
Data safety monitoring board
An independent data and safety monitoring board will
be established to review efficacy and safety data. The
DSMB will be made up of selected external individuals
with relevant expertise in medical abortion, biostatistics,
epidemiology and ethics. If the DSMB feels the data
confers significant harm or benefit associated with one
or more of the treatment arms and recommends discon-
tinuation, recruitment to the treatment arm or the entire
study may be stopped accordingly. Stopping rules will be
based on Haybittle-Peto boundaries for efficacy esti-
mates. One formal interim analyses of efficacy will be
performed when 50% of the expected sample size have
enrolled; no correction of the reported P value for these
interim tests will be performed. The board will also con-
sider safety data in making any decision to stop the
study. The board may consult with outside experts be-
fore making any decision regarding study termination or
continuation.
Ethics
The trial is being conducted in accordance with the
principles of Good Clinical Practice [38] Ethical approval
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for the study protocol has been granted both by the
WHO Ethics Review Committee and country-specific
review bodies including the Nepal Health Research
Council and the Ethics Review Board of the Ministry of
Health in Vietnam. It is currently undergoing review by
the Human Research Ethics Committee of the University
of Witwatersrand in Johannesburg, South Africa and
Allendale Investigational Review Board in Old Lyme,
Connecticut, USA; recruitment in South Africa will not
begin until all approvals are obtained.
All participants will provide written consent before
enrolling in the trial or commencing the follow-up
interview. All client records, written, recorded and tran-
scribed data will be de-identified and stored securely. No
names of participants (or others mentioned) or locations
will be used in the analysis or report writing. Confidentiality
will be maintained by assigning coded identifiers to
participant names (with a master list stored separately).
Participants will be able to withdraw at any point should
they no longer wish to remain in the study. Participants are
provided remuneration for expenses related to clinic and
telephone follow-up, but not for participation in the trial.
Discussion
It is important to recognize that though the report of
pain is common across settings where medical abortion
is provided, there has been little investigation into opti-
mal approaches to pain management outside of devel-
oped countries. Individual experiences of pain, responses
to pain and responses to pain medication are complex
and may differ according to ethnicity, socio-economic
status, cultural factors, physiology and genetics [39]. To
date, studies investigating ibuprofen to treat pain associated
with EMA report on predominantly populations of women
in the United States, Canada and Israel [9, 10, 13, 34]. In
contrast to prior studies, our proposal emphasizes investi-
gation of new pain management approaches in populations
of women from Africa and Asia.
WHO currently recommends vaginal, buccal and sub-
lingual routes for provision of misoprostol as part of a
combined mifepristone and misoprostol regimen for
medical abortion through 63 days’ gestation, and our
partner sites offer various recommended routes accord-
ing to their standard practice [12]. The safety and
effectiveness of the combined regimen is maintained
regardless of route of administration; however, there can
be differences in the frequency of side effects, including
pain, nausea, vomiting and diarrhea, due to variations in
pharmacokinetics that will need to be accounted for dur-
ing analysis and interpretation of our results [40].
Misoprostol provided sublingually is associated with the
fastest onset of action, the shortest time to peak concen-
tration (30 min), the highest peak concentration and
greatest bioavailability in comparison to other routes.
Both the buccal and vaginal misoprostol absorption
curves are similar, achieving a peak concentration at
around 60–80 min after administration, and the timing
and intensity of their effects on uterine contractility are
very similar. However, the drug levels attained by buccal
administration are consistently lower for six hours com-
pared to vaginal administration. The likelihood of side
effects is greatest for sublingual and lowest for buccal
administration.
Our main concerns regarding execution of this investi-
gation center on participants’ adequate adherence to
study procedures at home, including self-administration
of study medication and completing the diary to record
pain, timing of expulsion of pregnancy and symptoms
associated with the medical abortion process. The study
medications and additional analgesics will be packaged
and color-coded with clear instructions for use to facili-
tate ease of home administration. During training of
study staff, we will emphasize clear communication of
instructions for medication use and diary entry; all par-
ticipants will be encouraged to ask questions about
issues that are unclear as well as to contact the study
sites should concerns arise during the study. Import-
antly, we are planning to stage the roll out of the imple-
mentation of the study across countries. Following
completion of the first 30 participants enrolled in the
study at our first site, we will evaluate the feasibility of
our study procedures and amend them, if necessary, to
ensure quality data collection moving forward.
Additionally, we also hope to minimize participants’
loss to follow-up. Our partners have high-volume sites
offering medical abortion and report that a high propor-
tion of patients return for follow-up appointments to
confirm completion of the abortion. We are instituting
telephone contact on days 3 to 5 following mifepristone
administration to collect data relevant to our primary
objective. To encourage follow-up around day 14, women
will have the option for clinic (preferred) or telephone
contact. Should women not be able to physically return to
the clinic for follow-up, we will be able to complete the
follow-up questionnaires via telephone with participants.
Women will also be offered remuneration for their time
and travel associated with study procedures. These mea-
sures should attenuate significant loss to follow-up in our
investigation. We have accounted for a 10% loss-to-
follow-up rate in our sample size calculation; we do not
expect to exceed this anticipated loss.
Both ibuprofen and metoclopramide are included on
the WHO Essential Medicines List, globally available, and
relatively inexpensive [41]. Given that both medicines are
accessible and ibuprofen is already endorsed for use with
EMA in international and national guidelines, implemen-
tation of routine use of this regimen would be fairly easy if
any benefit to the pain experience was determined.
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Ideally, a simple approach to pain management is pref-
erable to a more complicated regimen requiring multiple
medications. If tramadol offered benefit, advocating for
its use with EMA would be easier to implement as a
single agent versus a multi-agent regimen. Currently, tram-
adol is not included on the WHO Essential Medicines List
or considered for routine use with EMA, but it is globally
registered and generally available with prescription. With
positive findings, use of tramadol in practice for this indica-
tion would likely be feasible, but might require additional
advocacy to ensure availability.
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